Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice
Doxorubicin (DOX) is a topoisomerase II inhibitor commonly used in the treatment of several types of cancer. Despite its efficacy, DOX can potentially cause fatal adverse effects, like cardiotoxicity. This work aimed to assess the role of inflammation in DOX-treated infant and adult mice and its pos...
Guardado en:
Autores principales: | Ana Reis-Mendes, Ana Isabel Padrão, José Alberto Duarte, Salomé Gonçalves-Monteiro, Margarida Duarte-Araújo, Fernando Remião, Félix Carvalho, Emília Sousa, Maria Lourdes Bastos, Vera Marisa Costa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec9e2f7caa8e4a5d832370426ace8b2f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting Oxidative Stress, NLRP3 Inflammasome, and Autophagy by Fraxetin to Combat Doxorubicin-Induced Cardiotoxicity
por: Ahmed M. Kabel, et al.
Publicado: (2021) -
Cardiomyocyte Stim1 Deficiency Exacerbates Doxorubicin Cardiotoxicity by Magnification of Endoplasmic Reticulum Stress
por: Zhu J, et al.
Publicado: (2021) -
NMCP‐2 polysaccharide purified from Morchella conica effectively prevents doxorubicin‐induced cardiotoxicity by decreasing cardiomyocyte apoptosis and myocardial oxidative stress
por: Na Xu, et al.
Publicado: (2021) -
Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival
por: Marija Kosić, et al.
Publicado: (2022) -
MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
por: Liuying Chen, et al.
Publicado: (2021)